BrainStorm Cell Therapeutics Inc. has announced that its common stock will be delisted from the Nasdaq Capital Market due to non-compliance with minimum shareholder equity requirements. Trading on Nasdaq will be suspended on July 18, 2025. The company has arranged for its shares to transition to the OTCQB Venture Market, where trading is expected to commence under the symbol BCLI on July 18, 2025, or shortly thereafter. CEO Chaim Lebovits emphasized that this change does not affect BrainStorm's mission or commitment to the development of NurOwn for ALS patients. The company remains focused on its scientific and clinical programs, including preparations for a pivotal Phase 3b trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN32700) on July 17, 2025, and is solely responsible for the information contained therein.